Abivax S.A.
Biotech developing oral drugs for chronic inflammatory diseases like colitis and Crohn's.
ABVX | NDAQ
Overview
Corporate Details
- ISIN(s):
- US00370M1036
- LEI:
- Country:
- United States of America
- Address:
- 7 BD HAUSSMANN, 0 PARIS
- Website:
- https://www.abivax.com/
- Sector:
- Mining and quarrying
- Industry:
- Mining of non-ferrous metal ores
Description
Abivax S.A. is a clinical-stage biotechnology company focused on developing therapeutics for chronic inflammatory diseases by harnessing the body's natural regulatory mechanisms. The company's lead drug candidate is obefazimod, an investigational, once-daily, orally administered small molecule. It features a novel mechanism of action as the first molecule designed to enhance the expression of miR-124, a microRNA that plays a critical role in regulating the immune response. Abivax's primary goal is the development and commercialization of obefazimod, initially targeting ulcerative colitis and Crohn’s disease. The company is also exploring the drug's potential in other inflammatory indications and developing follow-on compounds from its proprietary chemical library.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Abivax S.A. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Abivax S.A.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Abivax S.A. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
